Invokana Sales Figure Witness a Dip
Invokana Sales Figure Witness a Dip
Introduction
According to the fourth quarter 2017 sales earnings report released by J&J, Invokana made $262 million which was a 29% dip when compared to the previous reports. The low figures are reasoned to be due to the growing competition and awareness of the side-effects associated with this the Type 2 diabetes medication.
Comments
Latest News
Baltimore Wins $266M in Opioid Case Against Drug Distributors
Categories: Opioids
Baltimore has secured a $266 million victory in its lawsuit against major drug distributors McKesson and Cencora (formerly AmerisourceBergen), accusing them of fueling the…
DOJ Opposes JnJ’s Texas Bankruptcy Move in Talc Lawsuit Cases
Categories: Talcum
The U.S. Department of Justice (DOJ) recently opposed Johnson & Johnson’s latest attempt to use bankruptcy to resolve tens of thousands of…
First Valsartan Bellwether Trial to Focus on Cancer Lawsuits
Categories: Valsartan
The U.S. District Judge overseeing…